Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 10/20 | 0.76 |
| ▸ | TTK | P33981 | 6/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.76 |
| ▸ | INCENP | Q9NQS7 | 5/20 | 0.76 |
| ▸ | AURKA | O14965 | 4/20 | 0.76 |
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 3/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
| ▸ | GPR142 | Q7Z601 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850254 | 0.87 | ITK (0.78) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL5241521 | 0.87 | ITK (0.78) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062814 | 0.87 | ITK (1.00) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL15850097 | 0.86 | ITK (0.76) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062822 | 0.86 | ITK (1.00) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062836 | 0.83 | ITK (0.80) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL15850136 | 0.83 | TTK (0.80) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062850 | 0.83 | ITK (0.71) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062857 | 0.83 | ITK (0.71) | ITKTTKAURKBINCENPAURKA | |
| SCHEMBL10062866 | 0.83 | ITK (0.74) | ITKTTKAURKBINCENPAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885TTK 242/4885AURKB 167/4885 |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885TTK 242/4885AURKB 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.